The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 29, 2018

Filed:

Oct. 01, 2015
Applicant:

Oregon Health & Science University, Portland, OR (US);

Inventors:

Louis Picker, Portland, OR (US);

Jay A. Nelson, Lake Oswego, OR (US);

Klaus Frueh, Portland, OR (US);

Michael A. Jarvis, Portland, OR (US);

Scott G. Hansen, Portland, OR (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 7/00 (2006.01); A61K 39/00 (2006.01); C12N 15/86 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); A61K 39/08 (2006.01); A61K 39/13 (2006.01); A61K 39/145 (2006.01); A61K 39/275 (2006.01); C12N 15/869 (2006.01); C07K 14/16 (2006.01); C07K 14/045 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/08 (2013.01); A61K 39/12 (2013.01); A61K 39/13 (2013.01); A61K 39/145 (2013.01); A61K 39/275 (2013.01); C12N 15/86 (2013.01); C12N 15/869 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/552 (2013.01); A61K 2039/572 (2013.01); A61K 2039/58 (2013.01); C07K 14/005 (2013.01); C07K 14/045 (2013.01); C07K 14/16 (2013.01); C07K 14/161 (2013.01); C07K 14/162 (2013.01); C07K 14/163 (2013.01); C12N 2710/16111 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16141 (2013.01); C12N 2710/16143 (2013.01); C12N 2710/16162 (2013.01); C12N 2710/16171 (2013.01); C12N 2710/24134 (2013.01); C12N 2740/15022 (2013.01); C12N 2740/15034 (2013.01); C12N 2760/14134 (2013.01); C12N 2760/16134 (2013.01); C12N 2770/32634 (2013.01);
Abstract

The recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors of this invention encode heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.


Find Patent Forward Citations

Loading…